Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial

In this issue of The Journal of Nuclear Medicine, Iagaru et al. report an international, multicenter trial that compared coinjected 18F-fluoride and 18F-FDG PET/CT imaging with separate 18F-fluoride and 18F-FDG PET/CT scans in 115 patients with cancer (1). In the cohort of patients included in this trial, both 18F-fluoride and combined 18F-fluoride and 18F-FDG PET/CT scans detected more skeletal metastases in 48 subjects than did 18F-FDG alone, 29 of whom had no skeletal disease detected on 18F-FDG scans. 18F-FDG PET/CT scans detected extraosseous metastases in 48 patients. The combined 18F-fluoride/18F-FDG scans missed 3 lung nodules in 2 subjects and skull lesions in a further 2 subjects, but in none of these was overall staging affected.

[1]  Mohsen Beheshti,et al.  Prostate cancer: role of SPECT and PET in imaging bone metastases. , 2009, Seminars in nuclear medicine.

[2]  E. Mittra,et al.  Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study , 2009, Journal of Nuclear Medicine.

[3]  Peter Boesiger,et al.  Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. , 2010, Radiology.

[4]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[5]  J. Bono,et al.  Therapeutic Options for Advanced Prostate Cancer: 2011 Update , 2012, Current Urology Reports.

[6]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Blake,et al.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. , 2001, Seminars in nuclear medicine.

[8]  Z. Keidar,et al.  FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  G. Bauman,et al.  18F-fluorocholine for prostate cancer imaging: a systematic review of the literature , 2011, Prostate Cancer and Prostatic Diseases.

[11]  P. Waldenberger,et al.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Hans-Jürgen Gallowitsch,et al.  F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.

[13]  S. Groshen,et al.  Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer , 2012, Clinical nuclear medicine.

[14]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[15]  P. Clézardin.  Therapeutic targets for bone metastases in breast cancer , 2011, Breast Cancer Research.

[16]  D. Collins,et al.  Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. , 2011, Radiology.

[17]  E. Mittra,et al.  Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial , 2013, The Journal of Nuclear Medicine.

[18]  E. Nitzsche,et al.  Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? , 1998, Radiology.